US2183521028 - Common Stock
Looking for growth without the hefty price tag? Consider NASDAQ:CORT.
/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of the company's...
CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Corcept Therapeutics (NASDAQ:CORT) just reported results for the second quarter...
MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter...
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge.
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84th Scientific Sessions at a featured plenary session...
MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...